# Progressive EQUITY RESEARCH

# **IDOX** SOFTWARE & COMPUTER SERVICES

13 May 2025

### IDOX.L

56.2p

Market Cap: £258.6m



Source: LSE Data (priced as at prior close)

KEY DATA	
Net (debt)/cash	£(9.9)m <i>(at 31/10/24)</i>
Enterprise value	£268.5m
Index/market	AIM
Next news	Trading update, May
Shares in issue (m)	460.2
Chairman	Chris Stone
CEO	David Meaden
CFO	Anoop Kang

### COMPANY DESCRIPTION

Idox is a software business selling to UK public sector and global engineering clients. www.idoxplc.com

IDOX IS A RESEARCH CLIENT OF PROGRESSIVE

### ANALYSTS

#### Ian Robertson

+44 (0) 20 7781 5318



#### **Gareth Evans**

+44 (0) 20 7781 5301

gevans@progressive-research.com

# Accretive social care acquisition

Idox has today announced the acquisition of social care software provider Trojan Consultants Limited, which trades as Plianz, for an initial consideration of £7.65m. With revenues for year ended 31 March 2025 of c.£2.5m and an adjusted EBITDA margin of c.25%, management is confident that this will be an accretive deal. The products fit well with Idox's existing Social Care offering and the announcement cites a range of anticipated synergies and gains. We look forward to Idox's results in June as an opportunity to find out more and to update our estimates.

- Adding to Communities division. Idox has acquired Trojan Consultants Limited, trading as Plianz, for an initial cash consideration of £7.65m, from existing resources, with a potential maximum of £7.9m dependent upon revenue targets in its first year.
- Growing and profitable target. In the year to 31 March 2025, Plianz generated revenue of c.£2.5m with adjusted EBITDA margins of c.25%. On an EV/Sales and EV/EBITDA basis, this is a slight premium to the valuation of the wider group and, given the potential revenue and growth opportunities, consistent with management's confidence that the deal will be accretive.
- Products complement existing portfolio, plus AI. Plianz provides regulatory compliance software for local authorities and professional deputies in legal, financial management and local government operations, addressing the compliance challenges when dealing with the finances and estates of the vulnerable. This adds to Idox's public sector product portfolio, fitting alongside Idox's Social Care offering. A material part of the business appears to be AI related, highlighting that Idox is a true tech business and that potential AI opportunities exist within its markets.
- Growth synergies. Plianz should gain from Idox's skills and resources, and there should also be synergies in terms of customer reach and product offering in the social care market. It is anticipated that key management and personnel will remain at Idox following completion.
- Management still driving growth. While the focus of attention of late has been on the organic and acquisition opportunities in Land Property and Public Protection, it is clear from this deal that management is not ignoring the potential to add value with accretive acquisitions elsewhere in the group.

FYE OCT (£M)	2023	2024	2025E	2026E	2027E
Revenue	73.3	87.6	93.4	98.1	103.0
Adj EBITDA	24.5	26.1	26.9	29.2	31.2
Fully Adj PBT	15.8	16.1	16.1	18.4	20.5
Fully Adj EPS (p)	2.6	2.6	2.7	2.9	3.2
EV/Sales (x)	3.7x	3.1x	2.9x	2.7x	2.6x
EV/EBITDA (x)	11.0x	10.3x	10.0x	9.2x	8.6x
PER (x)	21.5x	21.6x	21.2x	19.2x	17.3x

Source: Company Information and Progressive Equity Research estimates.

This publication should not be seen as an inducement under MiFID II regulations. Please refer to important disclosures at the end of the document.



## Financial Summary: Idox

### Year end: October (£m unless shown)

PROFIT & LOSS	2023	2024	2025E	2026E	2027E
Revenue	73.3	87.6	93.4	98.1	103.0
Adj EBITDA	24.5	26.1	26.9	29.2	31.2
Adj EBIT	17.1	18.1	18.1	20.0	21.6
Reported PBT	7.8	8.1	9.5	11.7	13.8
Fully Adj PBT	15.8	16.1	16.1	18.4	20.5
NOPAT	11.9	11.9	12.3	13.6	15.2
Reported EPS (p)	1.2	1.2	1.5	1.9	2.2
Fully Adj EPS (p)	2.6	2.6	2.7	2.9	3.2
Dividend per share (p)	0.6	0.7	0.8	0.9	1.0
CASH FLOW & BALANCE SHEET	2023	2024	2025E	2026E	2027E
Operating cash flow	18.6	21.1	20.2	22.7	23.2
Free Cash flow	(3.9)	10.1	11.1	13.3	13.5
FCF per share (p)	(0.9)	2.2	2.4	2.9	2.9
Acquisitions	(14.1)	(2.4)	0.0	0.0	0.0
Disposals	0.0	0.0	0.0	0.0	0.0
Shares issued	(0.2)	(0.2)	0.0	0.0	0.0
Net cash flow	0.8	(3.5)	4.9	7.0	7.1
Overdrafts / borrowings/bonds	(29.5)	(21.6)	(21.6)	(21.6)	(21.6)
Cash & equivalents	14.8	11.7	16.6	23.6	30.7
Net (Debt)/Cash	(14.7)	(9.9)	(5.0)	2.0	9.1
NAV AND RETURNS	2023	2024	2025E	2026E	2027E
Net asset value	73.3	78.3	84.5	92.0	100.4
NAV/share (p)	16.1	17.0	18.3	19.9	21.6
Net Tangible Asset Value	(35.5)	(28.3)	(19.5)	(9.6)	1.4
NTAV/share (p)	(7.8)	(6.1)	(4.2)	(2.1)	0.3
Average equity	70.3	75.8	81.4	88.3	96.2
Post-tax ROE (%)	7.9%	6.9%	8.6%	9.8%	10.6%
METRICS	2023	2024	2025E	2026E	2027E
Revenue growth	N/A	19.5%	6.6%	5.0%	5.0%
Adj EBITDA growth		6.5%	3.2%	8.6%	6.8%
Adj EBIT growth		5.6%	0.3%	10.2%	8.0%
Adj PBT growth		2.4%	0.0%	13.9%	11.4%
Adj EPS growth		(0.4%)	1.7%	10.4%	11.0%
Dividend growth	N/A	16.7%	14.3%	13.8%	14.3%
Adj EBIT margins	23.4%	20.6%	19.4%	20.4%	21.0%
VALUATION	2023	2024	2025E	2026E	2027E
EV/Sales (x)	3.7	3.1	2.9	2.7	2.6
EV/EBITDA (x)	11.0	10.3	10.0	9.2	8.6
EV/NOPAT (x)	22.5	22.5	21.8	19.7	17.7
PER (x)	21.5	21.6	21.2	19.2	17.3
Dividend yield	1.1%	1.2%	1.4%	1.6%	1.9%
FCF yield	(1.6%)	4.0%	4.3%	5.1%	5.2%

Source: Company information and Progressive Equity Research estimates



#### **Disclaimers and Disclosures**

Copyright 2025 Progressive Equity Research Limited ("PERL"). All rights reserved. Progressive's research is commissioned by the subject company under contract and is freely available to the public and all institutional investors. Progressive does not offer investors the ability to trade securities. Our publications should not, therefore, be considered an inducement under MiFID II regulations. PERL provides professional equity research services, and the companies researched pay a fee in order for this research to be made available. This report has been commissioned by the subject company and prepared and issued by PERL for publication in the United Kingdom only. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable; however, PERL does not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of PERL at the time of publication, and any estimates are those of PERL and not of the companies concerned unless specifically sourced otherwise. PERL is authorised and regulated by the Financial Conduct Authority (FCA) of the United Kingdom (registration number 697355).

This document is provided for information purposes only, and is not a solicitation or inducement to buy, sell, subscribe, or underwrite securities or units. Investors should seek advice from an Independent Financial Adviser or regulated stockbroker before making any investment decisions. PERL does not make investment recommendations. Any valuation given in a research note is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. PERL does not undertake to provide updates to any opinions or views expressed in this document.

This document has not been approved for the purposes of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research. It is not subject to any prohibition on dealing ahead of the dissemination of investment research.

PERL does not hold any positions in the securities mentioned in this report. However, PERL's directors, officers, employees and contractors may have a position in any or related securities mentioned in this report. PERL or its affiliates may perform services or solicit business from any of the companies mentioned in this report.

The value of securities mentioned in this report can fall as well as rise and may be subject to large and sudden swings. In addition, the level of marketability of the shares mentioned in this report may result in significant trading spreads and sometimes may lead to difficulties in opening and/or closing positions. It may be difficult to obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance.



## Breadth of coverage

# **Analyst calibre**



To arrange a meeting with the management team, or for further information about Progressive, please contact us at: +44 (0) 20 7781 5300 info@progressive-research.com